Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10330136 | 0.87 | PIK3CD (0.77) | PIK3CDPIK3R1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12912425 | 0.86 | PIK3CD (0.75) | PIK3CDPIK3R1ADORA2AADORA2BADORA1 | |
| SCHEMBL13349721 | 0.85 | PIK3CD (0.74) | PIK3CDPIK3R1ADORA2AADORA2BADORA1 | |
| SCHEMBL12912410 | 0.83 | PIK3CD (1.00) | PIK3CDPIK3R1ADORA2AADORA2BADORA1 | |
| SCHEMBL1703532 | 0.82 | PIK3CD (0.69) | PIK3CDPIK3R1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10307720 | 0.81 | PIK3CD (1.00) | PIK3CDPIK3R1 | |
| SCHEMBL13261966 | 0.79 | PIK3CD (0.65) | PIK3CDPIK3R1ALDH1A1ADORA2AADORA2B | |
| SCHEMBL13506386 | 0.78 | PIK3CD (0.78) | PIK3CDPIK3R1ADORA2AADORA2BADORA1 | |
| SCHEMBL938576 | 0.78 | PIK3CD (1.00) | PIK3CDPIK3R1ADORA2AADORA2BADORA1 | |
| SCHEMBL360490 | 0.77 | PIK3CD (0.64) | PIK3CDPIK3R1ALDH1A1SMN1; SMN2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | claimed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | disclosed |
| US-20120178767-A1 | TREATMENT OF LIVER DISORDERS WITH P13K INHIBITORS | GILEAD CALISTOGA LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178767-A1 | TREATMENT OF LIVER DISORDERS WITH P13K INHIBITORS | GILEAD CALISTOGA LLC (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2441768-A1 | Thienopyrimidinones for treatment of inflammatory disorders and cancers | Eli Lilly & Co. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012009452-A1 | THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | 2011-06-09 | — | — | US | disclosed |
| WO-2011011550-A1 | TREATMENT OF LIVER DISORDERS WITH PI3K INHIBITORS | CALISTOGA PHARMACEUTICALS INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| WO-2008064018-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ELI LILLY & CO. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3R1 9/4885ALDH1A1 1821/4885 |
| US-20120178767-A1 | TREATMENT OF LIVER DISORDERS WITH P13K INHIBITORS | PYGL, PRKCZ, PHKG1 | PIK3CD 146/4885PIK3R1 554/4885ALDH1A1 1549/4885 |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R1 | PIK3CD 5/4885PIK3R1 3/4885ALDH1A1 4805/4885 |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | PIK3R5, PIK3C2A, PIK3C2B | PIK3CD 6/4885PIK3R1 8/4885ALDH1A1 4609/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3R1 5/4885ALDH1A1 4835/4885 |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R3 | PIK3CD 6/4885PIK3R1 4/4885ALDH1A1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.